# SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

> **NCT04033367** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 188 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04033367
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-22
- **Primary completion:** 2021-10-06
- **Final completion:** 2021-10-06
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033367, "SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04033367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*